Show simple item record

dc.contributor.authorLamarca, Angela
dc.contributor.authorBarriuso, Jorge
dc.contributor.authorMcNamara, Mairéad G
dc.contributor.authorHubner, Richard A
dc.contributor.authorManoharan, Prakash
dc.contributor.authorMansoor, Was
dc.contributor.authorValle, Juan W
dc.date.accessioned2020-02-27T16:55:20Z
dc.date.available2020-02-27T16:55:20Z
dc.date.issued2020en
dc.identifier.citationLamarca A, Barriuso J, McNamara MG, Hubner RA, Manoharan P, Mansoor W, et al. Temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration. Neuroendocrinology. 2020;110(1-2):155-7.en
dc.identifier.pmid31527383en
dc.identifier.doi10.1159/000503392en
dc.identifier.urihttp://hdl.handle.net/10541/622742
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1159/000503392en
dc.titleTemozolomide-capecitabine chemotherapy for neuroendocrine neoplasms: the dilemma of treatment durationen
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchesteren
dc.identifier.journalNeuroendocrinologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record